Blurbs

Analysts Offer Insights on Healthcare Companies: Cara Therapeutics (CARA) and Penumbra (PEN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cara Therapeutics (CARAResearch Report) and Penumbra (PENResearch Report) with bullish sentiments.

Cara Therapeutics (CARA)

Needham analyst Joseph Stringer reiterated a Buy rating on Cara Therapeutics today and set a price target of $26.00. The company’s shares closed last Thursday at $9.37.

According to TipRanks.com, Stringer is ranked 0 out of 5 stars with an average return of -23.6% and a 25.3% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Phathom Pharmaceuticals, and Lexicon Pharmaceuticals.

Currently, the analyst consensus on Cara Therapeutics is a Moderate Buy with an average price target of $28.00.

See Insiders’ Hot Stocks on TipRanks >>

Penumbra (PEN)

BTIG analyst Ryan Zimmerman maintained a Buy rating on Penumbra today and set a price target of $272.00. The company’s shares closed last Thursday at $125.34, close to its 52-week low of $114.87.

According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of 7.6% and a 43.4% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Treace Medical Concepts, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Penumbra is a Strong Buy with an average price target of $250.40.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CARA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos